New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment.

By F. Cervantes, B. Dupriez, Arturo Pereira, F. Passamonti, J. Reilly, E. Morra, A. Vannucchi, R. Mesa, J. Demory, G. Barosi and 2 more. Blood, 2008

1,253 citations recorded by the source corpus.

Subfields: Genetics, Hematology, Rheumatology

View Paper: https://www.semanticscholar.org/paper/36cb8f51d3a489ebd7f69af2e8fa05c8c41bb700

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. H. Kantarjian

In Hematology

1. H. Kantarjian
2. Brian J. Druker

In Rheumatology

1. H. Kantarjian

Citations in the corpus

• JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. (2012, neutral): “Grade 2 42 (29) 1 (1) 8 (5) 28 (19) 5 (3)”
• A Double-Blind Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis (2012, background): “Principal causes of death in the ruxolitinib group were muscle weakness, subdural hematoma, renal failure, non-small cell lung cancer, acute myeloid leukemia (AML), pneumonia (2), sepsis (2); principal causes of death in the placebo group were staphylococcal infection, gastrointestinal hemorrhage, i”